FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Proposes to Deny Hetlioz sNDA

FDA explains why it is proposing to refuse to approve a Vanda sNDA for a new indication for Hetlioz.

latest-news-card-1
Human Drugs

Drug Outsourcing Group/FDA Settle Law Suit

The Outsourcing Facilities Association and FDA reach a settlement agreement that compels the agency to promptly review long-pending nominations for ac...

Medical Devices

Marked Change Seen in FDA Final CDS Guidance

Hyman, Phelps & McNamara attorneys and a medical device regulatory expert say an FDA final guidance on clinical decision support software will generat...

latest-news-card-1
Human Drugs

More Quality Issues at Lilly Plant: Reuters

Reuters reports that FDA has again found quality issues at the Lilly Branchburg, NJ, drug manufacturing facility.

latest-news-card-1
Human Drugs

Priority Review for Gilead Trodelv sBLA

FDA accepts for priority review a Gilead Sciences supplemental BLA for Trodelv (sacituzumab govitecan-hziy) for treating certain adult patients with u...

latest-news-card-1
Human Drugs

CGMP Violations at Mexicos Eksa Mills

FDA warns Mexicos Eksa Mills about CGMP violations in its manufacturing of finished drugs.

latest-news-card-1
Federal Register

EUA Revoked For Covid-19 Test

Federal Register: FDA revokes an emergency use authorization issued to Laboratorio Clinico Toledo, Puerto Rico, for its Laboratorio Clinico Toledo SAR...

latest-news-card-1
Human Drugs

Dupixent Filing for Eosinophilic Esophagitis Next Year

Regeneron Pharmaceuticals and Sanofi say they will seek FDA approval next year for Dupixent (dupilumab) and its use in treating children with active e...

latest-news-card-1
Federal Register

Draft Guide on ANDA Facility Inspection Readiness

Federal Register notice: FDA makes available a draft guidance entitled Facility Readiness: Goal Date Decisions Under GDUFA.

latest-news-card-1
Human Drugs

FDA Rejects Supernus NDA for Parkinsons Drug

FDA sends Supernus Pharmaceuticals a complete response letter on its NDA for SPN-830 (apomorphine) infusion device for the continuous treatment of mot...